offline
AbbVie Slips in Spite of Earnings Beat, Guidance Boost
AbbVie slips despite beating first-quarter estimates and raising full-year guidance.
...
The North Chicago, Illinois-based company reported earnings of $2.46 billion, or $1.65 a share, compared with $2.78 billion, or $1.74 a share, a year ago. Adjusted earnings came to $2.14 a share, beating the FactSet estimate of $2.06.
Revenue totaled $7.8 billion, roughly in line with analysts' estimates. Sales of the Crohn's disease treatment drug Humira came to $4.45 billion, down 5.6% from a year ago, but beat analysts' projections of $4.38 billion.
The company also raised its guidance for 2019 to $8.73 to $8.83 a share from $8.65 to $8.75, representing 11% growth at the mid-point.
...
https://www.thestreet.com/investing/abbv...yptr=yahoo
![[Bild: ABBVc1dl1508.png]](https://finviz.com/publish/042519/ABBVc1dl1508.png)
AbbVie slips despite beating first-quarter estimates and raising full-year guidance.
...
The North Chicago, Illinois-based company reported earnings of $2.46 billion, or $1.65 a share, compared with $2.78 billion, or $1.74 a share, a year ago. Adjusted earnings came to $2.14 a share, beating the FactSet estimate of $2.06.
Revenue totaled $7.8 billion, roughly in line with analysts' estimates. Sales of the Crohn's disease treatment drug Humira came to $4.45 billion, down 5.6% from a year ago, but beat analysts' projections of $4.38 billion.
The company also raised its guidance for 2019 to $8.73 to $8.83 a share from $8.65 to $8.75, representing 11% growth at the mid-point.
...
https://www.thestreet.com/investing/abbv...yptr=yahoo
__________________
